Alpha Tau Wins FDA Approval to Expand Recurrent Glioblastoma Trial to 20 Patients

• Alpha Tau Medical received FDA clearance to expand its U.S. Alpha DaRT REGAIN trial for recurrent glioblastoma to 20 patients from 10.
• The expanded protocol broadens eligibility to IDH-mutant grade 4 tumors, adding survival and quality-of-life assessments.
• An additional interim analysis is planned six months following the fifth patient's treatment in July 2026.
• New trial data will be presented November 13 at the Society for Neuro-Oncology's 2026 annual meeting, building on interim results released May 11.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-110531), on October 19, 2026, and is solely responsible for the information contained therein.